Perrigo Company plc filed a Form 8-K on October 29, 2026, disclosing that it entered into a definitive agreement to sell its Infant Formula business, with a press release attached as Exhibit 99.1 pursuant to Regulation FD.

Key Highlights

  • Definitive agreement signed: Perrigo announced entry into a definitive agreement to sell its Infant Formula business, according to the filing.
  • Disclosure date: The press release announcing the transaction was issued on October 29, 2026.
  • Regulation FD filing: The disclosure was made under Item 7.01 of the current report and is furnished, not filed, for purposes of Section 18 of the Securities Exchange Act of 1934.
  • Signed by CFO: The filing was signed by Eduardo Bezerra, Chief Financial Officer of Perrigo Company plc.
  • Exchange listing: Perrigo's ordinary shares trade on the NYSE under the symbol PRGO, with multiple series of notes also listed on the NYSE.

Perrigo Discloses Infant Formula Business Sale Agreement

Perrigo Company plc (NYSE:PRGO), incorporated in Ireland, disclosed on October 29, 2026, that it has entered into a definitive agreement to sell its Infant Formula business. The announcement was made through a press release attached to the current report as Exhibit 99.1 and was furnished to the SEC under Item 7.01 covering Regulation FD disclosures. The filing states that Perrigo "undertakes no obligation to update, supplement or amend the press release attached hereto as Exhibit 99.1."

According to the filing, the information provided under Item 7.01 and in Exhibit 99.1 "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section." The filing further notes that this information shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such a filing.

In addition to its ordinary shares (PRGO), Perrigo has several series of notes registered on the New York Stock Exchange, including 5.150% Notes due 2030 (PRGO30), 6.125% Notes due 2032 (PRGO32A), 5.375% Notes due 2032 (PRGO32B), 5.300% Notes due 2043 (PRGO43), and 4.900% Notes due 2044 (PRGO44), according to the securities registration table in the filing. The report was signed by Eduardo Bezerra, identified as Chief Financial Officer.

What Was Disclosed

Perrigo Company plc filed a current report disclosing its entry into a definitive agreement to sell its Infant Formula business as of October 29, 2026. The announcement was furnished under Regulation FD and is not deemed filed for Exchange Act liability purposes.